Enhancing Quality Mindset
The PDA India Chapter Annual Meeting 2026 took place from August 3-, 2026, at the Novotel Hyderabad Convention Centre in Hyderabad.
Centered on the theme "Enhancing Quality Mindset Amid Changing Regulatory Expectations & Sustaining Supply Resilience – Beyond Inspection to Quality Excellence," the 3-day event convened pharma
The PDA India Chapter Annual Meeting 2026 was designed to address real-world challenges faced across manufacturing, quality, and operations. The three-day technical meeting brought together profession-als from the pharmaceutical and biopharmaceutical sectors to examine current manufacturing challenges, evolving regulatory requirements and approaches to strengthening quality and operational performance.
Structured through parallel tracks for pharma and biopharma, the meeting addressed sector-specific requirements while also providing opportunities for cross-functional learning. The sessions combined regulatory perspectives, technical presentations, real-world case studies, industry contributions and peer discussions. The emphasis throughout was on translating regulatory and technical developments into approaches that can be applied within manufac-turing and quality operations.
Key Areas of Focus
The meeting covered a broad range of issues relevant to contemporary pharmaceutical and biopharma-ceutical manufacturing. Key discussions focused on inspection readiness, regulatory responses, data integrity, quality culture and risk-based decision-making, particularly in sterile manufacturing environ-ments.
The implementation of EU GMP Annex 1 was exam-ined alongside several critical aspects of contamina-tion control. These included environmental monitor-ing, media fills, isolators and Restricted Access Barrier Systems (RABS), as well as strategies for identifying and controlling contamination risks.
Other sessions addressed CAPA effectiveness, investigations, human error and recurring deviations, with emphasis on identifying root causes and developing sustainable corrective and preventive measures. Discussions also considered how organisa-tions can strengthen their quality systems and ensure that quality principles are consistently reflected in day-to-day operations.
Regulatory and Operational Perspectives
Regulatory developments and inspection expectations formed an important compo-nent of the meeting. Perspectives from leading regulatory bodies provided an understanding of the direction in which industry requirements are evolving and the implications for manufacturing organisations.
Inspection readiness was discussed not simply as preparation for an inspection, but as an ongoing aspect of maintaining robust systems and demonstrating effective control.
Sessions on regulatory responses explored the importance of accurate assessment, appropriate corrective actions and effective communica-tion when addressing regulatory observations.
Operational efficiency and resilience were also considered alongside compliance. The discussions highlighted the need to balance regulatory requirements with practical manufacturing realities and to develop systems capable of maintaining consistent performance under changing operational conditions.
Cross-Functional Learning
The meeting was designed for professionals across Quality Assurance, Quality Operations, Production and Manufacturing, Operations, Engineering, Microbiology, Regulatory Affairs and Research and Development. It also catered to senior managers and executive leaders involved in parenteral, API, oral dosage form and biologics operations.
Bringing these functions together enabled issues to be considered from different operational perspectives. Challenges involving contamination control, investiga-tions, deviations, engineering systems and manufac-turing processes often require coordinated action across multiple departments, making cross-functional understanding particularly important.
Real-World Case Studies and Industry Contributions
Case studies and interactive discus-sions provided an opportunity to examine challenges in the context of actual manufacturing and shop-floor conditions. Rather than limiting discussions to regulatory theory, the sessions explored how organisations can respond to practical problems and improve existing systems.
Poster presentations and industry contributions further comple-mented the technical sessions by showcasing innovations, process improvements and best practices developed by industry teams. These contributions provided examples of how organisations are addressing common challenges and implementing improve-ments within their own operations.
Industry Interaction and Networking
The meeting also provided a platform for profession-als to interact with peers, experts and decision-makers from across the industry. Discussions and networking sessions facilitated the exchange of experiences and perspectives on regulatory, technical and operational issues.
This interaction added value to the formal sessions by enabling professionals to compare approaches, discuss common challenges and gain perspectives from organisations operating in different areas of the pharmaceutical and biopharmaceutical sectors.